A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.

A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.

View in: PubMed

subject areas

Benzothiazoles
CCR5 Receptor Antagonists
Clinical Trials, Phase II as Topic
Double-Blind Method
Drug Therapy, Combination
Humans
Imidazoles
Isoxazoles
Liver Cirrhosis
Multicenter Studies as Topic
Non-alcoholic Fatty Liver Disease
Randomized Controlled Trials as Topic
Receptors, CCR2
Receptors, Cytoplasmic and Nuclear
Sulfoxides
Treatment Outcome

authors with profiles

Michael Charlton
Mary Rinella